Beneficial Ownership Report · SCHEDULE 13G/A
Stoke Therapeutics, Inc.
STOKNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- STOKE THERAPEUTICS INC
- Company CIK
- 0001623526
- Street
- 45 WIGGINS AVENUE
- City
- BEDFORD
- State / country code
- MA
- Postal code
- 01730
Statement details
- Amendment number
- 5
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- FMR LLC
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 4,820,462.07
- Percent of class
- 7.5
- Sole voting power
- 4,819,851.00
- Shared voting power
- 0.00
- Sole dispositive power
- 4,820,462.07
- Shared dispositive power
- 0.00
Reporting person 2
- Name
- Abigail P. Johnson
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 4,820,462.07
- Percent of class
- 7.5
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 4,820,462.07
- Shared dispositive power
- 0.00
Item 1
Issuer
STOKE THERAPEUTICS INC
Principal executive office address
45 WIGGINS AVENUE,BEDFORD,MA,USA,01730
Item 2
Citizenship
Not applicable
Filing person
FMR LLC
Principal business or residence address
245 Summer Street, Boston, Massachusetts 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
7.5
Amount beneficially owned
4820462.07
Sole voting power
Please see the responses to Items 5 and 6 on the cover page.
Shared voting power
0.00
Sole dispositive power
4820462.07
Shared dispositive power
0.00
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of STOKE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of STOKE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7
Not applicable indication
N
Subsidiaries
See attached Exhibit 99.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Please see Exhibit 99 for 13d-1(k) (1) agreement.
Signature comments
* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Signature 1
- Reporting person
- FMR LLC
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
- Date
- 11/04/2026
Signature 2
- Reporting person
- Abigail P. Johnson
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
- Date
- 11/04/2026
Filed exhibits
- EX-99 ↗exhibit99.txt
Company context
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.
Current securities
Recent company filings
- 10-Q filingNov 3, 2026
- Results of Operations and Financial ConditionOct 29, 2026
- 144 filingOct 21, 2026
- SCHEDULE 13G - filed by BIOTECHNOLOGY VALUE FUND L P regarding Stoke Therapeutics, Inc.Sep 30, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 25, 2026